Angiotensin receptor blocker telmisartan: efficacy, safety and relevance of clinical application

• Main Authors: Maksimov M.L., Dralova O.V.
• Format: Article
• Language: Russian
• Published: IP Morozov P.V. 2017-02-01
• Series: Системные гипертензии
• Subjects: telmisartan; angiotensin receptor blockers; angiotensin II receptor antagonists; efficiency; safety; interchangeability; therapeutic equivalence; bioequivalence; arterial hypertension; antihypertensive therapy; renin-angiotensin-aldosterone system
• Online Access: http://syst-hypertension.ru/en/archive/2017/vol-14-1-2017/angiotensin-receptor-blocker-telmisartan-efficacy-safety-and-relevance-of-clinical-application_1797/
• ISSN: 2075-082X; 2542-2189

Angiotensin receptor blocker telmisartan is a modern and effective antihypertensive drug which has advantages in comparison with other drugs of the group of angiotensin receptor blockers. Long half-life retains its effect is significant more than 24 hours, which is especially important for blood pressure control in the dangerous morning hours. Telmisartan is excreted by the kidneys less than 2%, making its use safe in patients with renal pathology. High antihypertensive efficacy combined with its excellent tolerability. Telmisartan has the greatest affinity to PPARg-receptors, which is especially important when selecting antihypertensive therapy in patients with arterial hypertension and metabolic disorders, insulin resistance, metabolic disorders. A considerable number of studies showing the effectiveness of treatment with telmisartan in patients with cardiovascular disease, diabetes, metabolic syndrome, nephropathy. The article presents the results of a study of therapeutic equivalence of generic drug is telmisartan, which showed a high bioequivalence to original brand-name formulation and was according to the indications: hypertension and decrease cardiovascular morbidity and mortality in patients aged 55 years and older with a high risk of cardiovascular disease. The results of our observations show comparable antihypertensive efficacy of the original and generic products and well tolerated by the results of questioning of patients.